Department of Physics and Astronomy, Texas Christian University, Fort Worth, 76129, USA.
Interdiscip Sci. 2024 Dec;16(4):844-853. doi: 10.1007/s12539-024-00643-w. Epub 2024 Jul 21.
The development of antiviral treatments for SARS-CoV-2 was an important turning point for the pandemic. Availability of safe and effective antivirals has allowed people to return back to normal life. While SARS-CoV-2 antivirals are highly effective at preventing severe disease, there have been concerning reports of viral rebound in some patients after cessation of antiviral treatment. In this study, we use a mathematical model of viral infection to study the potential of different antivirals to prevent viral rebound. We find that antivirals that block production are most likely to result in viral rebound if the treatment time course is not sufficiently long. Since these antivirals do not prevent infection of cells, cells continue to be infected during treatment. When treatment is stopped, the infected cells will begin producing virus at the usual rate. Antivirals that prevent infection of cells are less likely to result in viral rebound since cells are not being infected during treatment. This study highlights the role of antiviral mechanism of action in increasing or reducing the probability of viral rebound.
抗病毒药物的开发是 SARS-CoV-2 大流行的一个重要转折点。安全有效的抗病毒药物的出现使人们能够恢复正常生活。虽然 SARS-CoV-2 抗病毒药物在预防重症疾病方面非常有效,但在停止抗病毒治疗后,一些患者出现病毒反弹的令人担忧的报告。在这项研究中,我们使用病毒感染的数学模型来研究不同抗病毒药物预防病毒反弹的潜力。我们发现,如果治疗时间不够长,抑制病毒生成的抗病毒药物最有可能导致病毒反弹。因为这些抗病毒药物并不能阻止细胞感染,所以在治疗期间细胞会继续被感染。当治疗停止时,受感染的细胞将开始以通常的速度产生病毒。预防细胞感染的抗病毒药物不太可能导致病毒反弹,因为在治疗期间细胞没有被感染。这项研究强调了抗病毒作用机制在增加或减少病毒反弹概率方面的作用。